IDH2 and central nervous system cancer: These variants are characterized by conferring a specific enzymatic activity that converts alpha-ketoglutarate to 2-hydroxyglutarate; the accumulation of this oncometabolite in gliomas with IDH mutations profoundly affects several cellular processes [12], including metabolic reprogramming, because the Krebs cycle adjusts to compensate for fluctuations in the pathways.